A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2001
11/22/2001	WO2001087844A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
11/22/2001	WO2001087841A1 Novel polymorph v of torasemide
11/22/2001	WO2001087840A1 Propanoic acid derivatives as integrin receptor antagonists
11/22/2001	WO2001087828A1 N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
11/22/2001	WO2001087823A1 Novel aryl, alkenyl, and alkynl 4-dedimethylaminotetracycline derivatives
11/22/2001	WO2001087810A1 Methods for the production of d-chiro-inositol and the use of d-chiro-inositol obtained therefrom
11/22/2001	WO2001087350A2 Treatment of human papillomavirus (hpv)-infected cells
11/22/2001	WO2001087348A2 Multifunctional nanodevice platform
11/22/2001	WO2001087346A2 Dendritic cells loaded with toxic substances
11/22/2001	WO2001087343A2 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	WO2001087337A1 Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
11/22/2001	WO2001087336A1 Cancer treatments by using a combination of an antibody against her2 and interleukin -2
11/22/2001	WO2001087334A1 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
11/22/2001	WO2001087333A2 Immune system stimulating means
11/22/2001	WO2001087329A1 Liquid pharmaceutical composition containing an erythropoietin derivate
11/22/2001	WO2001087328A2 Interleukin-1 inhibitors in the treatment of diseases
11/22/2001	WO2001087325A1 Method to increase class i presentation of exogenous antigens by human dendritic cells
11/22/2001	WO2001087313A1 Combination chemotherapy
11/22/2001	WO2001087307A2 Compositions and methods for the treatment of cancer
11/22/2001	WO2001087306A2 Compositions and methods for the treatment of colorectal cancer
11/22/2001	WO2001087299A1 Aralkyl ester soft drugs
11/22/2001	WO2001087297A1 Cannabinoid drugs
11/22/2001	WO2001087296A1 Methods for decreasing cell proliferation based on (3r, 4r)δ8-tetrahydrocannabinol-11-oic acids
11/22/2001	WO2001087295A1 Methods for decreasing cell proliferation based on (3r, 4r)-δ8-tetrahydrocannabinol-11-oic acids
11/22/2001	WO2001087283A2 New use of citreamicins
11/22/2001	WO2001087272A2 Encapsulating a toxic core within a non-toxic region in an oral dosage form
11/22/2001	WO2001087267A1 Protein matrix materials, devices and methods of making and using thereof
11/22/2001	WO2001087265A2 Pharmaceutical form of administration for peptides, methods for its production and use
11/22/2001	WO2001087254A1 Use of ellagic acid as anti-pollution cosmetic agent
11/22/2001	WO2001087239A2 Methods of affecting laminin 5 processing
11/22/2001	WO2001087238A2 Induction of apoptosis and cell growth inhibition by protein 4.33
11/22/2001	WO2001087234A2 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers
11/22/2001	WO2001087227A2 Drug containing polymeric micelles
11/22/2001	WO2001087039A2 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2
11/22/2001	WO2001055333A8 Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides
11/22/2001	WO2001042246A3 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
11/22/2001	WO2001036977A3 Identification of disease markers involving mass-based-separation
11/22/2001	WO2001036650A3 An oncolytic adenovirus
11/22/2001	WO2001036476A3 Ing2, an iaps associated cell cycle protein, compositions and methods of use
11/22/2001	WO2001035995A3 Tr3-specific binding agents and methods for their use
11/22/2001	WO2001035991A3 Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
11/22/2001	WO2001034792A3 Compositions and methods for the diminution or elimination of various cancers
11/22/2001	WO2001034116A3 Pharmaceutical formulations comprising labdanes for the treatment of tumors or leukemias
11/22/2001	WO2001034093A3 Potentiation of prodrug efficacy
11/22/2001	WO2001032891A3 Human lipase
11/22/2001	WO2001031036A3 Modified viral surface proteins which bind to cells of tumor vasculature
11/22/2001	WO2001030781A3 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
11/22/2001	WO2001027268A3 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
11/22/2001	WO2001027146A3 Chemokine receptor
11/22/2001	WO2001027116A3 Condensed dihydroquinolinone derivatives for inhibiting mrp1
11/22/2001	WO2001025239A3 Oxazinoquinolones useful for the treatment of viral infections
11/22/2001	WO2001019380A3 Oncolytic virus
11/22/2001	WO2001018169A3 Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases
11/22/2001	WO2001015679A3 Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders
11/22/2001	WO2001014564A3 Polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby
11/22/2001	WO2001011063A3 Gene transfer combination vectors, method for the production and utilization thereof
11/22/2001	WO2001000242A3 Polycation-based bioconjugates
11/22/2001	WO2000066165A8 Contraceptive compositions containing quinazolinone and benzoxazine derivatives
11/22/2001	WO2000056681A9 Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction
11/22/2001	WO2000055633A9 Methods of screening for colorectal cancer modulators
11/22/2001	WO2000010600A9 Activation and protection of t-cells (cd4+ and cd8+) using an h¿2? receptor agonist and other t-cell activating agents
11/22/2001	US20010044937 Transgenic intracytoplasmic sperm injection, retroviral gene transfer, intracytoplasmic nuclear injection, and pronuclear injection; useful as models for human disease/diagnosis, assessing safety and efficiency of drug and gene therapy
11/22/2001	US20010044537 Inhibit human factor Xa; treating thrombotic activity; 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((2-(1,2 -dihydoxyethyl)-4-hydroxy-5-ethoxytetrahydrofuran-3-yl)oxy)-pyridin-2 -yl)oxy)4-hydroxybenzamidine
11/22/2001	US20010044536 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
11/22/2001	US20010044535 Heterocyclic compounds containing a guanidine mimic, for inhibition of cell adhesion, treatment of angiogenesis disorders, inflammation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration
11/22/2001	US20010044466 Anticancer and antitumor agents
11/22/2001	US20010044465 Use of L-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
11/22/2001	US20010044459 Hydroxamic acid derivatives
11/22/2001	US20010044451 Tyrosine kinase inhibitors
11/22/2001	US20010044442 Dimethoxy quinazolines for treating diabetes
11/22/2001	US20010044440 Modulators of p38 MAP kinase
11/22/2001	US20010044436 Bicyclic inhibitors of glycogen synthase kinase 3
11/22/2001	US20010044435 Antitumor agents, treatment of the lungs and respiratory tract
11/22/2001	US20010044433 Specific antitumor activity against breast, colon, lung, prostate cancers and melanomas
11/22/2001	US20010044421 Antimutagenic compositions for treatment and prevention of photodamage to skin
11/22/2001	US20010044419 Administering to skin a composition containing deoxyribonucleosides in concentrations sufficient to enhance DNA repair or reduce mutation frequency in a vehicle capable of delivering deoxyribonucleosides to skin cells
11/22/2001	US20010044416 Administering an antigen and a CD4+ T helper (Th2) cell immunostimulatory nucleic acid mucosally or dermally to produce an antigen specific immune response; treating autoimmune diseases, cancer, infections
11/22/2001	US20010044148 EBV-infected stomach cancer cell line
11/22/2001	US20010044144 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
11/22/2001	US20010043915 Method for administering a cytokine to the central nervous system and the lymphatic system
11/22/2001	US20010043914 In situ vaccination by administering to a tumor a slow-release microparticle containing Interferon-12; antigrowth, -tumor, -carcinogenic and -metastasis agents; with or without a synergistic cytokine
11/22/2001	US20010042551 Method and system for use in treating a patient with a biological substance to optimize therapy and prevent an adverse response
11/22/2001	DE10023492A1 New 2-(((hetero)aryl-alkyl)-amino)-aza-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases
11/22/2001	DE10023484A1 New 2-((cycloalkyl- or heterocyclyl-alkyl)-amino)-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases
11/22/2001	CA2781858A1 Modulators of tnf-.alpha. signaling
11/22/2001	CA2762960A1 Recrystallization processes for obtaining anhydrous optically active lansoprazole
11/22/2001	CA2410067A1 Combination chemotherapy
11/22/2001	CA2410056A1 Induction of apoptosis and cell growth inhibition by protein 4.33
11/22/2001	CA2409746A1 Immunotoxin fusion proteins and means for expression thereof
11/22/2001	CA2409740A1 Novel aryl, alkenyl, and alkynyl 4-dedimethylaminotetracycline desrivatives
11/22/2001	CA2409699A1 Novel polymorph v of torasemide
11/22/2001	CA2409652A1 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
11/22/2001	CA2409445A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/22/2001	CA2409361A1 Humanised antibodies to the epidermal growth factor receptor
11/22/2001	CA2409225A1 Tricyclic pyrazole derivatives
11/22/2001	CA2409068A1 Novel dual oxidases as mitogenic and endocrine regulators
11/22/2001	CA2409044A1 Improved recrystallization processes for obtaining anhydrous optically active lansoprazole
11/22/2001	CA2409035A1 Hydroxamic acid derivatives
11/22/2001	CA2409005A1 Methods for decreasing cell proliferation based on (3r, 4r)-.delta.8-tetrahydrocannabinol-11-oic acids
11/22/2001	CA2408974A1 Cancer treatments by using a combination of an antibody against her2 and interleukin -2

1 ... 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 ... 2211